Tomoyuki Kakizume
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.
Journal: Pharmaceutical statistics
Published: December 06, 2025
BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
Journal: Statistical methods in medical research
Published: March 06, 2024
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 07, 2022
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
Journal: Cancer science
Published: December 10, 2018
Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
Journal: Pharmaceutical statistics
Published: June 15, 2018
Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
Journal: Cancer science
Published: August 24, 2017
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.
Journal: Cancer chemotherapy and pharmacology
Published: October 20, 2016
A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies.
Journal: Therapeutic innovation & regulatory science
Published: March 01, 2014
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Journal: Cancer science
Published: September 15, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026